转移性头颈癌：免疫治疗及其他

IF 2.6 3区医学 Q3 ONCOLOGY

Seminars in Radiation Oncology Pub Date : 2025-03-14 DOI:10.1016/j.semradonc.2025.02.004

Kirsten V. Nguyen , Cody M. Lebeck Lee , Jennifer H. Choe

{"title":"转移性头颈癌：免疫治疗及其他","authors":"Kirsten V. Nguyen , Cody M. Lebeck Lee , Jennifer H. Choe","doi":"10.1016/j.semradonc.2025.02.004","DOIUrl":null,"url":null,"abstract":"<div><div>Head and neck cancer is estimated to result in 71,000 new cancer diagnoses and 16,000 deaths in 2024. Of these cases, approximately 14% will be metastatic. Recent changes in treatment paradigms have established immunotherapy as a cornerstone of treatment in the metastatic and recurrent setting. While immunotherapy has undoubtedly improved outcomes and can lead to long term durable responses in select patients, overall response rates remain suboptimal, with approximately 13%-20% of patients responding to immunotherapy in most studies. This review aims to provide an overview of the current treatment landscape of immunotherapies in head and neck malignancies. Additionally, we aim to discuss the future of immunotherapy, as well as novel targets and therapeutic platforms that may continue to change the treatment paradigm in this disease.</div></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"35 2","pages":"Pages 259-270"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metastatic Head and Neck Cancer: Immunotherapy and Beyond\",\"authors\":\"Kirsten V. Nguyen , Cody M. Lebeck Lee , Jennifer H. Choe\",\"doi\":\"10.1016/j.semradonc.2025.02.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Head and neck cancer is estimated to result in 71,000 new cancer diagnoses and 16,000 deaths in 2024. Of these cases, approximately 14% will be metastatic. Recent changes in treatment paradigms have established immunotherapy as a cornerstone of treatment in the metastatic and recurrent setting. While immunotherapy has undoubtedly improved outcomes and can lead to long term durable responses in select patients, overall response rates remain suboptimal, with approximately 13%-20% of patients responding to immunotherapy in most studies. This review aims to provide an overview of the current treatment landscape of immunotherapies in head and neck malignancies. Additionally, we aim to discuss the future of immunotherapy, as well as novel targets and therapeutic platforms that may continue to change the treatment paradigm in this disease.</div></div>\",\"PeriodicalId\":49542,\"journal\":{\"name\":\"Seminars in Radiation Oncology\",\"volume\":\"35 2\",\"pages\":\"Pages 259-270\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1053429625000098\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429625000098","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

据估计，到2024年，头颈癌将导致7.1万例新的癌症诊断和1.6万例死亡。在这些病例中，大约14%会转移。最近治疗模式的变化已经确立了免疫治疗作为转移性和复发性肿瘤治疗的基石。虽然免疫治疗无疑改善了结果，并且可以在选定的患者中产生长期持久的反应，但总体反应率仍然不理想，在大多数研究中，大约13%-20%的患者对免疫治疗有反应。本文综述了目前头颈部恶性肿瘤免疫疗法的治疗概况。此外，我们的目标是讨论免疫治疗的未来，以及可能继续改变这种疾病治疗模式的新靶点和治疗平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Metastatic Head and Neck Cancer: Immunotherapy and Beyond

Head and neck cancer is estimated to result in 71,000 new cancer diagnoses and 16,000 deaths in 2024. Of these cases, approximately 14% will be metastatic. Recent changes in treatment paradigms have established immunotherapy as a cornerstone of treatment in the metastatic and recurrent setting. While immunotherapy has undoubtedly improved outcomes and can lead to long term durable responses in select patients, overall response rates remain suboptimal, with approximately 13%-20% of patients responding to immunotherapy in most studies. This review aims to provide an overview of the current treatment landscape of immunotherapies in head and neck malignancies. Additionally, we aim to discuss the future of immunotherapy, as well as novel targets and therapeutic platforms that may continue to change the treatment paradigm in this disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in Radiation Oncology 医学-核医学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.